7634 Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02823 Filed 2–10–15; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: GE Healthcare 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before March 13, 2015. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before March 13, 

2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. Comments 

and request for hearings on applications 

to import narcotic raw material are not 

appropriate. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispenser, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on 

September 12, 2014, GE Healthcare, 

3350 North Ridge Avenue, Arlington 

Heights, Illinois 60004–1412 applied to 

be registered as an importer of cocaine 

(9041), a basic class of controlled 

substance listed in schedule II. 

The company plans to import small 

quantities of ioflupane, in the form of 

three separate analogues of cocaine, to 

validate production and quality control 

systems, for a reference standard, and 

for producing material for a future 

investigational new drug (IND) 

submission. 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02826 Filed 2–10–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Mallinckrodt LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before March 13, 2015. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before March 13, 

2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. Comments 

and requests for hearings on 

applications to import narcotic raw 

material are not appropriate. 72 FR 3417 

(January 25, 2007). 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on January 

16, 2014, Mallinckrodt LLC, 3600 North 

Second Street, St. Louis, Missouri 

63147, applied to be registered as an 

importer of the following basic classes 

of controlled substances: 

Controlled substance Schedule 

Phenylacetone (8501) .................. II 

Coca Leaves (9040) ..................... II 

Opium, raw (9600) ....................... II 

Poppy Straw Concentrate (9670) II 

The company plans to import the 

listed controlled substances for the 

manufacture of controlled substances in 

bulk for distribution to its customers. 

In reference to Phenylacetone (8501), 

the company plans to import the 

controlled substance for the bulk 

manufacture of amphetamine products 

for sale to its customers. 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02824 Filed 2–10–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Siegfried 

USA, LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before April 13, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 


tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices 7635 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix of subpart, R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on 

November 17, 2014, Siegfried USA, 

LLC, 33 Industrial Park Road, 

Pennsville, New Jersey 08070 applied to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Controlled substance Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Dihydromorphine (9145) ............... I 

Hydromorphinol (9301) ................. I 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Opium tincture (9630) .................. II 

Oxymorphone (9652) ................... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02821 Filed 2–10–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Cambridge 

IsotoPE LAB 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic class, and applicants 

therefore, may file written comments on 

or objections to the issuance of the 

proposed registration in accordance 

with 21 CFR 1301.33(a) on or before 

April 13, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on August 

12, 2014, Cambridge Isotope Lab, 50 

Frontage Road, Andover, Massachusetts 

01810 applied to be registered as a bulk 

manufacturer of morphine (9300), a 

basic class of controlled substance listed 

in schedule II. 

The company plans to utilize small 

quantities of the listed controlled 

substance in the preparation of 

analytical standards. 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02820 Filed 2–10–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: INSYS 

Therapeutics, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before April 13, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, and 

dispensers, of controlled substances 

(other than final orders in connection 

with suspension, denial, or revocation 

of registration) has been redelegated to 

the Deputy Assistant Administrator of 

the DEA Office of Diversion Control 

(‘‘Deputy Assistant Administrator’’) 

pursuant to section 7 of 28 CFR part 0, 

appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on October 

17, 2014, Insys Therapeutics, Inc., 2700 

Oakmont, Round Rock, Texas 78665 

applied to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Controlled substance Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

The company plans to manufacture 

bulk synthetic active pharmaceutical 

ingredients (APIs) for product 

development and distribution to its 

customers. No other activity for this 

drug code is authorized for this 

registration. 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02819 Filed 2–10–15; 8:45 am] 

BILLING CODE 4410–09–P 


tkelley on DSK3SPTVN1PROD with NOTICES